OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board and management of Singular Genomics Systems, Inc. in relation to a merger agreement with Deerfield Management Company, L.P. [1][2] Group 1: Investigation Details - The investigation aims to determine if Singular Genomics' board acted in the best interest of shareholders during the merger process [2] - Singular Genomics announced a definitive merger agreement on December 23, 2024, where it will be acquired for $20.00 per share in an all-cash transaction [2] Group 2: Legal Representation - The Schall Law Firm offers free consultations to discuss shareholder rights and potential claims related to the investigation [3] - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3]